Hydroxyethyl starch enhances fibrinolysis in human plasma by diminishing α2-antiplasmin–plasmin interactions
- 1 October 2007
- journal article
- Published by Wolters Kluwer Health in Blood Coagulation & Fibrinolysis
- Vol. 18 (7) , 647-656
Abstract
Hydroxyethyl starch (HES) solutions are effective volume expanders but are also associated with poorly understood coagulopathy. Enhanced fibrinolysis following dilution with HES has been demonstrated. This investigation sought to identify the interactions of HES with critical fibrinolytic/antifibrinolytic enzymes. Normal plasma or plasmas deficient in factor XIII, thrombin activatable fibrinolysis inhibitor or alpha2-antiplasmin were either not diluted or were diluted 20% with 0.9% NaCl, 5% human albumin, high-molecular-weight HES (HES 450) or low-molecular-weight HES (HES 130). Plasma was activated with celite and exposed to 75 IU/ml tissue-type plasminogen activator. Coagulation growth/disintegration kinetics were determined with thrombelastography. Compared with undiluted plasma, diluted plasma had a significant decrease in the clot lysis time and the time to maximum rate of lysis in all plasma types except in alpha2-antiplasmin-deficient plasma. The hierarchy of the decrease in clot lysis time and time to maximum rate of lysis was HES 450 = HES 130 > 5% human albumin = 0.9% NaCl. In conclusion, HES dilution enhances fibrinolysis by diminishing alpha2-antiplasmin-plasmin interactions. Further laboratory and clinical investigation is warranted to better define the mechanisms by which HES enhances clot disintegration and to find new therapeutic roles for HES to either prevent or treat thrombosis.Keywords
This publication has 20 references indexed in Scilit:
- Hemodilution Modulates the Time of Onset and Rate of Fibrinolysis in Human and Rabbit PlasmaThe Journal of Heart and Lung Transplantation, 2006
- Tranexamic acid does not correct the haemostatic impairment caused by hydroxyethyl starch (200 kDa/0.5) after cardiac surgeryBlood Coagulation & Fibrinolysis, 2006
- Efficacy of fibrinogen and prothrombin complex concentrate used to reverse dilutional coagulopathy—a porcine modelBritish Journal of Anaesthesia, 2006
- Effects of Hextend Hemodilution on Plasma Coagulation Kinetics in the Rabbit: Role of Factor XIII-Mediated Fibrin Polymer CrosslinkingJournal of Surgical Research, 2006
- The Effect of Fibrinogen Substitution on Reversal of Dilutional Coagulopathy: An In Vitro ModelAnesthesia & Analgesia, 2006
- Effects of PentaLyte® and Voluven® hemodilution on plasma coagulation kinetics in the rabbit: role of thrombin‐fibrinogen and factor XIII‐fibrin polymer interactionsActa Anaesthesiologica Scandinavica, 2005
- Antithrombin efficiency is maintained in vitro in human plasma following dilution with hydroxyethyl starchesBlood Coagulation & Fibrinolysis, 2005
- Colloids decrease clot propagation and strength: role of factor XIII‐fibrin polymer and thrombin–fibrinogen interactionsActa Anaesthesiologica Scandinavica, 2005
- Thrombelastographic whole blood clot formation after ex vivo addition of plasma substitutes: improvements of the induced coagulopathy with fibrinogen concentrateBritish Journal of Anaesthesia, 2004
- Evaluation of a New Hydroxyethyl Starch, Preparation (Hextend™) on Selected Coagulation ParametersClinical and Applied Thrombosis/Hemostasis, 1995